[go: up one dir, main page]

HK1208672A1 - 用於對腦內所蓄積的 蛋白質進行成像的新的化合物 - Google Patents

用於對腦內所蓄積的 蛋白質進行成像的新的化合物

Info

Publication number
HK1208672A1
HK1208672A1 HK15109324.1A HK15109324A HK1208672A1 HK 1208672 A1 HK1208672 A1 HK 1208672A1 HK 15109324 A HK15109324 A HK 15109324A HK 1208672 A1 HK1208672 A1 HK 1208672A1
Authority
HK
Hong Kong
Prior art keywords
tau
novel compound
imaging
brain
protein accumulated
Prior art date
Application number
HK15109324.1A
Other languages
English (en)
Inventor
樋口真人
須原哲也
丸山將浩
張明榮
島田齊
Original Assignee
Nat Inst Radiolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Inst Radiolog filed Critical Nat Inst Radiolog
Publication of HK1208672A1 publication Critical patent/HK1208672A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK15109324.1A 2012-12-21 2015-09-23 用於對腦內所蓄積的 蛋白質進行成像的新的化合物 HK1208672A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2012/083286 WO2014097474A1 (ja) 2012-12-21 2012-12-21 脳内に蓄積したタウタンパク質をイメージングするための新規化合物

Publications (1)

Publication Number Publication Date
HK1208672A1 true HK1208672A1 (zh) 2016-03-11

Family

ID=50287280

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109324.1A HK1208672A1 (zh) 2012-12-21 2015-09-23 用於對腦內所蓄積的 蛋白質進行成像的新的化合物

Country Status (12)

Country Link
US (4) US10604516B2 (zh)
EP (1) EP2767532B1 (zh)
JP (1) JP5422782B1 (zh)
KR (2) KR20190136125A (zh)
CN (2) CN107412788B (zh)
AU (2) AU2012397435B2 (zh)
CA (1) CA2894994C (zh)
DK (1) DK2767532T3 (zh)
HK (1) HK1208672A1 (zh)
SG (1) SG11201504901PA (zh)
TW (1) TWI627166B (zh)
WO (1) WO2014097474A1 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10604516B2 (en) 2012-12-21 2020-03-31 National Institutes For Quantum And Radiological Science And Technology Compounds for imaging tau proteins that accumulate in the brain
KR102005068B1 (ko) * 2015-03-27 2019-07-30 주식회사 휴엔 1,2 나프토퀴논 유도체 및 이의 제조방법
CN105985299B (zh) * 2015-11-10 2018-10-12 济南大学 一种高选择性超灵敏分析二价铁离子的荧光探针
CN106008374B (zh) * 2016-06-07 2018-07-27 四川大学 吡嗪类化合物及其在医药上的用途
CN106632139A (zh) * 2016-12-13 2017-05-10 青岛科技大学 苯并噻唑‑2‑甲醛及其衍生物合成的新方法
WO2018164184A1 (ja) * 2017-03-10 2018-09-13 国立大学法人滋賀医科大学 神経難病の画像診断薬及び体外診断薬
WO2019026797A1 (ja) * 2017-07-31 2019-02-07 国立大学法人静岡大学 凝集タンパク質の検出に適した化合物
GB201712567D0 (en) 2017-08-04 2017-09-20 Karin & Sten Mortstedt Cbd Solutions Ab Selective ligands for tau aggregates
JP6831802B2 (ja) * 2018-01-12 2021-02-17 上海富吉医療器械有限公司Ｓｈａｎｇｈａｉ Ｃｈａｒｔｗｅｌｌ Ｍｅｄｉｃａｌ Ｉｎｓｔｒｕｍｅｎｔ Ｃｏ．， Ｌｔｄ． 放射性核種標識化合物及びこれを含有するイメージング剤
JP7293343B2 (ja) * 2018-05-09 2023-06-19 アプリノイア セラピューティクス リミテッド ヘテロアリール化合物及びその使用
WO2020174963A1 (ja) 2019-02-27 2020-09-03 国立研究開発法人量子科学技術研究開発機構 αシヌクレイン凝集体結合剤及びイメージング方法
CA3161455A1 (en) 2019-11-13 2021-05-20 Aprinoia Therapeutics Limited Compounds for degrading tau protein aggregates and uses thereof
KR102344676B1 (ko) 2020-02-12 2021-12-30 한국과학기술연구원 타우 응집체에 선택적으로 결합하는 근적외선 형광 탐침자로서 유효한 신규 화합물 및 이의 제조방법
JP2023518202A (ja) * 2020-03-18 2023-04-28 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド Ｐｅｔトレーサーｐｂｂ３に基づく異常タウの標的化ディグレーダー
AU2021331023A1 (en) * 2020-08-25 2023-04-06 Eisai R&D Management Co., Ltd. Novel compound, alpha-synuclein aggregate binder, and use thereof
EP4484425A1 (en) 2022-02-24 2025-01-01 National Institutes for Quantum Science and Technology Novel compound, alpha-synuclein aggregate binder, and use thereof
CN115894384A (zh) * 2022-08-30 2023-04-04 同济大学 喹喔啉类荧光探针、方法及应用
CN115353498B (zh) * 2022-09-01 2023-08-08 坛墨质检科技股份有限公司 一种苯并噻唑类锌离子荧光探针及其制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833863A (en) * 1971-12-27 1974-09-03 Eastman Kodak Co Styryl and arylbutadienyl dye lasers
JPS5553333A (en) 1978-10-16 1980-04-18 Hitachi Ltd Composite type electrophotographic plate
JPS61275836A (ja) 1985-05-31 1986-12-05 Fuji Photo Film Co Ltd ハロゲン化銀写真乳剤
US5264329A (en) 1989-09-18 1993-11-23 Dupont (U.K.) Limited Radiation sensitive compositions
GB8921116D0 (en) * 1989-09-18 1989-11-01 Du Pont Improvements in or relating to radiation sensitive compositions
HU230375B1 (hu) 2000-08-24 2016-03-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Tioflavin-származékok és alkalmazásuk az Alzheimer-kór diagnózisában és kezelésében
CA2465554A1 (en) * 2002-12-16 2004-06-16 Bf Research Institute, Inc. Quinoline derivatives as probes for the diagnosis of diseases in which tau protein accumulates
AU2004240649A1 (en) 2003-05-19 2004-12-02 Irm, Llc Immunosuppressant compounds and compositions
CA2500358A1 (en) * 2003-08-13 2005-02-24 Bf Research Institute, Inc. Probes for diseases in which amyloid accumulates, agents for staining amyloid, drugs for treatment and prophylaxis of diseases with accumulated amyloid, and probes for diagnosis of neurofibrillary tangles and agents for staining neurofibrillary tangles
WO2005016384A1 (ja) * 2003-08-13 2005-02-24 Bf Research Institute, Inc. アミロイド蓄積性疾患のプローブ、アミロイド染色剤、アミロイド蓄積性疾患の治療および予防薬、ならびに神経原線維変化の診断プローブおよび染色剤
WO2005058374A1 (en) * 2003-12-15 2005-06-30 Tongji Medical Center Methods and compositions for modulating tau in vivo
EP1854781A1 (en) * 2005-02-28 2007-11-14 Taisho Pharmaceutical Co., Ltd Radioactive halogen-labeled phenyloxyaniline derivatives
JP2007106755A (ja) 2005-09-13 2007-04-26 Japan Health Science Foundation アミロイドイメージング用プローブ
WO2007034282A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
AU2006320556A1 (en) 2005-12-01 2007-06-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Isotopically-labeled benzothiazole compounds as imaging agents for amyloidogenic proteins
TW200736252A (en) * 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
US7678819B2 (en) * 2006-12-07 2010-03-16 The Trustees Of The University Of Pennsylvania Acetylene derivatives and their use for binding and imaging amyloid plaques
EP2103611A4 (en) 2006-12-25 2010-06-30 Univ Tohoku benzoxazole
CN101293878B (zh) * 2007-04-25 2010-12-15 中国科学院上海应用物理研究所 苯并噻唑苯胺类化合物及其制备方法和应用
SI2247558T2 (sl) 2008-02-14 2024-10-30 Eli Lilly And Company Nova kontrastna sredstva za zaznavanje nevroloških disfunkcij
US8557222B2 (en) 2008-04-04 2013-10-15 Avid Radiopharmaceuticals, Inc. Radiopharmaceutical imaging of neurodegenerative diseases
CA2731738A1 (en) 2008-07-24 2010-01-28 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying ad pathology
WO2010017094A2 (en) * 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
US8193363B2 (en) 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
EP2338059B1 (en) 2008-09-23 2015-04-08 WisTa Laboratories Ltd. Ligands for aggregated tau molecules
US20120035187A1 (en) * 2009-01-29 2012-02-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Anti-neurodegenerative disease agent
WO2010087315A1 (ja) * 2009-01-29 2010-08-05 株式会社林原生物化学研究所 抗アルツハイマー病剤
EP2411057B1 (en) * 2009-03-23 2020-05-06 Eli Lilly and Company Imaging agents for detecting neurological disorders
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
KR101116234B1 (ko) * 2009-10-29 2014-03-06 (주)퓨쳐켐 (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
US9133343B2 (en) 2009-11-30 2015-09-15 Enzo Biochem, Inc. Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications
AU2012249917B2 (en) * 2011-04-26 2017-06-15 Biojiva Llc Neurodegenerative disorders and muscle diseases implicating PUFAs
WO2012175458A1 (en) 2011-06-22 2012-12-27 F. Hoffmann-La Roche Ag A method for the identification of beta-sheet aggregated protein ligands
US10604516B2 (en) 2012-12-21 2020-03-31 National Institutes For Quantum And Radiological Science And Technology Compounds for imaging tau proteins that accumulate in the brain
US9447054B2 (en) 2014-01-15 2016-09-20 Korea Institute Of Radiological & Medical Sciences Anticancer supplement agent including benzo[D]oxazol derivative as effective ingredient
WO2015188368A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016132998A1 (ja) 2015-02-19 2016-08-25 Jnc株式会社 ベンゾチオフェンを有する液晶性化合物、液晶組成物および液晶表示素子
KR102616762B1 (ko) 2015-03-18 2023-12-20 아비나스 오퍼레이션스, 인코포레이티드 타겟화된 단백질들의 향상된 분해를 위한 화합물들 및 방법들
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
TW201722957A (zh) 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
TW201722958A (zh) 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
US10059878B2 (en) 2016-02-17 2018-08-28 Jnc Corporation Liquid crystal composition and liquid crystal display device
JP6696312B2 (ja) 2016-06-15 2020-05-20 Jnc株式会社 液晶組成物および液晶表示素子
AU2017295608B2 (en) 2016-07-12 2024-01-04 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau and methods of use thereof
CA3030754C (en) 2016-07-20 2022-04-26 Anahit Ghochikyan Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
CA3042260C (en) 2016-11-01 2023-10-03 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
US10723717B2 (en) 2016-12-23 2020-07-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
ES2965049T3 (es) 2017-07-12 2024-04-10 Dana Farber Cancer Inst Inc Compuestos para la degradación de la proteína tau
JP7293343B2 (ja) 2018-05-09 2023-06-19 アプリノイア セラピューティクス リミテッド ヘテロアリール化合物及びその使用
CA3102214A1 (en) 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Ligands to cereblon (crbn)
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
JP7548992B2 (ja) 2019-07-17 2024-09-10 アルビナス・オペレーションズ・インコーポレイテッド タウタンパク質標的化化合物および関連する使用方法

Also Published As

Publication number Publication date
US10604516B2 (en) 2020-03-31
EP2767532B1 (en) 2016-07-13
AU2012397435A1 (en) 2015-08-06
SG11201504901PA (en) 2015-07-30
CN104736524A (zh) 2015-06-24
CN107412788A (zh) 2017-12-01
US12195454B2 (en) 2025-01-14
AU2017204357A1 (en) 2017-08-10
CN104736524B (zh) 2017-06-23
EP2767532A1 (en) 2014-08-20
WO2014097474A1 (ja) 2014-06-26
CA2894994C (en) 2019-11-12
US20220056020A1 (en) 2022-02-24
US20240083893A1 (en) 2024-03-14
US20200262829A1 (en) 2020-08-20
JP5422782B1 (ja) 2014-02-19
TW201441214A (zh) 2014-11-01
CA2894994A1 (en) 2014-06-26
EP2767532A4 (en) 2014-09-10
KR20150095610A (ko) 2015-08-21
CN107412788B (zh) 2021-06-18
AU2012397435B2 (en) 2017-03-30
JPWO2014097474A1 (ja) 2017-01-12
US11667628B2 (en) 2023-06-06
TWI627166B (zh) 2018-06-21
US20150239878A1 (en) 2015-08-27
DK2767532T3 (en) 2016-09-12
AU2017204357B2 (en) 2019-04-18
KR20190136125A (ko) 2019-12-09
KR102053484B1 (ko) 2019-12-06

Similar Documents

Publication Publication Date Title
HK1208672A1 (zh) 用於對腦內所蓄積的 蛋白質進行成像的新的化合物
IL289241A (en) Antibodies to tau
HK1205269A1 (zh) 包括堆叠式集成元件的通電眼科鏡片
EP2856759A4 (en) STEREOSCOPIC VIDEO IMAGING
EP2831821A4 (en) COLLECTION POINTS
ZA201406100B (en) Filter element
ZA201500873B (en) Switchable exhale filter system
EP2911296A4 (en) COMMON MODE FILTER
EP2745157A4 (en) IMAGING OBJECTIVE
SG2013083357A (en) Filter element
GB201418163D0 (en) Techniques for video compression
EP2761353A4 (en) FIGURE LENS
ZA201408213B (en) Anti-transglutaminase 2 antibodies
EP2932327A4 (en) DOUBLE Q IMAGING SYSTEM
EP2718759A4 (en) IMAGING LENSES
GB201421555D0 (en) Seismic imaging
GB201217225D0 (en) Image filtering
EP2687147A4 (en) IMAGING SYSTEM
SG10201707733WA (en) Novel compounds for imaging tau proteins that accumulate in brain
GB201218552D0 (en) Imaging system
GB201200934D0 (en) Imaging fluorophores